Cytokinetics EVP sells shares after option exercise
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock. On May 1, 2026, he exercised a non-qualified stock option covering 15,857 shares of common stock at $37.63 per share and sold 15,857 shares of common stock in an open-market transaction at $65.00 per share.
Following these transactions, Callos directly held 58,555 shares of Cytokinetics common stock. The exercised option had originally been scheduled to vest in equal monthly installments over four years until fully vested.
Insider Trade Summary 10b5-1
Exercise and Sale: 15,857 shares ($434K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Callos Andrew
Role
EVP, Chief Commercial Officer
Sold
15,857 shs ($1.03M)
Approx. gross sale proceeds
$1.03M
Approx. exercise cost
$597K
Approx. pre-tax spread
$434K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 15,857 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,857 | $37.63 | $597K |
| Sale | Common Stock | 15,857 | $65.00 | $1.03M |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 58,555 shares (Direct)
Footnotes (1)
- F1. This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.
Key Figures
Shares sold: 15,857 shares
Sale price: $65.00 per share
Option exercise size: 15,857 shares
+2 more
5 metrics
Shares sold
15,857 shares
Common stock sold in open-market transaction on May 1, 2026
Sale price
$65.00 per share
Price for 15,857 Cytokinetics common shares sold
Option exercise size
15,857 shares
Non-qualified stock option exercised into common stock
Option exercise price
$37.63 per share
Exercise price of non-qualified stock option
Post-transaction holdings
58,555 shares
Cytokinetics common stock directly held after transactions
Key Terms
Non-Qualified Stock Option, open-market sale, derivative security, vesting
4 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (Right to Buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"This option shall vest and become exercisable over 4 years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Cytokinetics (CYTK) executive Andrew Callos report?
Andrew Callos reported exercising options and selling Cytokinetics shares. He exercised a non-qualified stock option for 15,857 common shares at $37.63 and sold 15,857 common shares in an open-market transaction at $65.00, all dated May 1, 2026.
What option exercise did Andrew Callos report for Cytokinetics (CYTK)?
Andrew Callos exercised a non-qualified stock option for 15,857 Cytokinetics common shares. The option had an exercise price of $37.63 per share and was fully exercised on May 1, 2026, converting the option into common stock before the reported sale.
What is the role of Andrew Callos at Cytokinetics (CYTK) in this Form 4 filing?
In this Form 4 filing, Andrew Callos is identified as Cytokinetics’ EVP, Chief Commercial Officer. The filing details his personal transactions in Cytokinetics common stock, including an option exercise and an open-market sale completed on May 1, 2026.
How did the exercised Cytokinetics (CYTK) option held by Andrew Callos vest?
The non-qualified stock option exercised by Andrew Callos vested over four years. Shares underlying the option vested in equal monthly installments so that the option became 100% vested four years from the date of grant, according to the footnote disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
